Saturday 17 October 2026 Export AHCO’s income statement to Excel — free account

AdaptHealth Corp.

In the quarter to June 2026, revenue grew 12.7%, EPS fell 1,090.0%, free cash flow fell 128.6% and total debt rose 4.30%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years; insiders bought in the last twelve months.

6.02 0.37 −5.79%

Follow AHCO

Alert me

Market cap: $871.2M
P/E: 0.0×
Fwd P/E: 13.2×
Dividend yield: —
F-score: 4/9
Altman Z: 0.91
Beneish M: −3.26
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 49.34

Total sells 0.28

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	2	4	—	—	—	—	3	—	—
Sell	—	1	—	—	—	—	—	1	1	—	—	—

Insider Ownership 36.56%

Capital & Financial Ratios $m

Market Cap 871.24

Revenue 3,369.98

Net Income (223.38)

Free Cash Flow 99.12

Net Debt 1,870.08

Current Ratio 1.12

Debt/Equity 1.38

P/E ratio 0.00

Fwd P/E 13.20

P/S ratio 0.24

P/B ratio 0.59

Past 5Y EPS Growth —

This Y EPS Growth (132.73%)

Next Y EPS Growth 87.28%

Next Y revenue growth (11.34%)

Next 5Y EPS Growth (20.87%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.28%

10-year low 10-year high

P/B against its own 10 years 4.01%

10-year low 10-year high

EV/Sales against its own 10 years 2.28%

10-year low 10-year high

EV/FCF against its own 10 years 61.35%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	77	110	106	43
Receivables	389	408	371	390
Inventory	114	140	151	105
Other	—	53	—	168
	649	756	729	797

	2023	2024	2025	Q'26
Payables	392	438	554	576
ST’ Debt	53	16	20	8
Other	53	68	90	69
	537	567	712	709

Compound Annual Growth %

	10y	5y	3y
Sales	—	24.83%	2.99%
Cash Flow	—	25.20%	17.19%
Earnings	—	0.00%	0.00%
Book Value	—	40.29%	(10.90%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	820	740	—	—	—
’25	778	657	820	990	3,245
’24	792	806	806	857	3,261
’23	745	793	804	858	3,200
’22	706	728	756	780	2,971
’21	482	617	653	713	2,465
’20	191	232	284	363	1,071

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	94	145	—	—	—
’25	96	162	161	183	602
’24	49	198	144	150	542
’23	140	86	99	155	481
’22	66	103	107	97	374
’21	18	129	27	101	276
’20	24	87	34	50	196

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(21)	—	—	—
’25	0	73	67	79	219
’24	(39)	117	90	73	241
’23	51	4	22	67	143
’22	(11)	26	13	(46)	(18)
’21	(17)	85	(33)	37	72
’20	17	83	22	33	156

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.12)	(0.99)	—	—	—
’25	(0.05)	0.10	0.16	(0.76)	(0.52)
’24	(0.02)	0.13	0.15	0.34	0.61
’23	0.12	0.09	(3.43)	(1.91)	(5.31)
’22	0.30	0.09	0.11	(0.02)	0.33
’21	(0.03)	0.59	0.42	0.15	1.19
’20	0.00	0.08	(1.08)	(1.60)	(3.70)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	9.60	7.82	10.29	18.24	11.40	6.37	6.46	7.11	Analyst estimates 2026–2028 Powerpack
	High	—	—	10.00	12.77	39.76	41.58	27.48	22.94	11.90	11.63
People
People	Employees	—	—	—	2,590	4,700	10,700	10,900	10,700	10,500	10,900
	Revenue/emp, $m	—	—	0.00	0.20	0.23	0.23	0.27	0.30	0.31	0.30
Income, $m
Income, $m	Revenue	—	—	345	530	1,071	2,465	2,971	3,200	3,261	3,245
	Gross margin, %	—	—	15.03	16.79	16.07	18.51	19.53	19.50	20.89	18.77
	EBT	—	0	22	(22)	(206)	191	98	(724)	136	(15)
	EBT margin, %	—	0.00	6.44	(4.13)	(19.24)	7.75	3.30	(22.62)	4.17	(0.47)
	Net income	—	0	24	(23)	(194)	158	73	(675)	95	(66)
	Depreciation	—	—	50	64	90	267	356	1,219	384	516
Per share, $
Per share, $	Revenue	—	0.00	29.02	23.48	20.40	19.52	22.14	23.85	24.38	24.01
	Earnings	—	—	2.05	(1.00)	(3.70)	1.12	0.47	(5.06)	0.62	(0.52)
	Cash flow	—	0.00	5.75	2.68	3.73	2.18	2.79	3.58	4.05	4.45
	Capex	—	0.00	(0.84)	(0.95)	(0.76)	(1.61)	(2.92)	(2.52)	(2.25)	(2.83)
	Free cash flow	—	0.00	4.91	1.73	2.97	0.57	(0.13)	1.07	1.80	1.62
	Book value	—	0.00	8.64	(1.69)	5.35	16.36	16.08	10.93	11.80	11.29
	Shares, m	—	31	12	23	52	126	134	134	134	135
Valuation, ×
Valuation, ×	P/E	—	—	4.81	0.00	0.00	21.84	40.29	0.00	15.61	0.00
	P/S	—	—	0.00	0.47	1.84	1.25	0.87	0.30	0.39	0.41
	P/B	—	—	1.14	0.00	7.02	1.49	1.20	0.66	0.81	0.88
	EV/Sales	—	—	0.00	1.08	2.48	2.09	1.60	0.96	0.97	0.93
	EV/FCF	—	—	3.31	14.68	17.04	71.07	(270.04)	21.42	13.15	13.71
Cash, $m
Cash, $m	Operating cash flow	—	—	68	60	196	276	374	481	542	602
	Capex	—	—	(10)	(21)	(40)	(203)	(391)	(337)	(301)	(382)
	Free cash flow	—	—	58	39	156	72	(18)	143	241	219
Balance, $m
Balance, $m	Working capital	—	0	(45)	27	(59)	170	129	112	189	17
	Total debt	—	0	134	403	785	2,204	2,192	2,171	2,006	1,769
	Net debt	—	0	109	326	685	2,054	2,146	2,094	1,896	1,663
	Shareholders’ equity	—	0	103	(38)	281	2,067	2,158	1,467	1,578	1,526
Returns, %
Returns, %	ROA	—	0.00	12.60	(4.66)	(13.70)	4.01	1.21	(13.96)	2.01	(1.61)
	ROIC	—	0.00	9.17	6.38	4.62	3.42	2.77	(10.50)	4.74	1.78
	ROE	—	0.00	45.26	(66.05)	(133.20)	12.08	3.00	(37.46)	5.94	(4.56)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IART Integra LifeSciences Holdings Corporation	$1.1B	— (loss-making)	26.1×	+0.76% (above 0%: growing)	n/m	+193.48% (above 0%: growing)	52.47%	4.61%	Compare
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
QDEL QuidelOrtho Corporation	$953.9M	— (loss-making)	— (loss-making)	+2.77% (above 0%: growing)	n/m	−61.45% (below 0%: shrinking)	43.26%	(3.46%)	Compare
BBNX Beta Bionics, Inc.	$933.8M	— (loss-making)	— (loss-making)	+37.76% (above 0%: growing)	n/m	−1.87% (below 0%: shrinking)	59.04%	(79.90%)	Compare
SIBN SiBone	$892.3M	— (loss-making)	— (loss-making)	+15.18% (above 0%: growing)	n/m	+60.12% (above 0%: growing)	79.54%	(8.58%)	Compare
AHCO AdaptHealth Corp.	$871.2M	— (loss-making)	13.2×	+12.66% (above 0%: growing)	n/m	−128.56% (below 0%: shrinking)	14.08%	(18.61%)
INMD InMode Ltd.	$824.0M	11.3×	11.8×	−0.01% (below 0%: shrinking)	−30.95% (below 0%: shrinking)	−12.63% (below 0%: shrinking)	74.82%	12.82%	Compare
VREX VAREX IMAGING	$784.3M	34.7×	43.4×	+3.69% (above 0%: growing)	n/m	+757.14% (above 0%: growing)	36.44%	10.83%	Compare
Median of peers	$943.8M	—	20.2×	+5.76%	—	+29.12%	55.76%	0.58%

All 149 Medical Devices stocks →

AdaptHealth Corp. (AHCO) key facts

AdaptHealth Corp. (AHCO) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AHCO traded at $6.02, a market capitalization of $871.2 million.
Return on equity was −4.56% and debt-to-equity 1.38.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.91 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.